Researchers move forward with shot to prevent Lyme disease

(WKOW) — Lyme Disease cripples hundreds of people in Wisconsin each year and now researchers are working on a shot to prevent the problem.

The Badger State is a hot spot for the tick-borne disease. According to the Centers for Disease Control and Prevention, the average number of cases has more than doubled over the last decade. In 2018, Wisconsin saw 1,121 cases.

Now researchers are looking for a way to prevent the spread of Lyme disease with medicine.

“You give the shot right at the beginning of the season,” said Dr. Mark Klempner, a researcher from the University of Massachusettes Medical School. “Take the shot sometime in March or April and then we are anticipating that it would work for eight months.”

The shot will enter the human testing phase this spring.

Monday on 27 News at 10, we explore what this shot could mean for you and your family ahead of tick season.

By Rebecca Ribley, Wake Up Wisconsin Anchor


For more:


Valneva Vaccine Targets Six OspA Serotypes

Two researchers warned several years ago that new Lyme disease vaccines using the outer surface protein (OspA) must be thoroughly tested for safety. They said, “Any new Lyme vaccine will need extensive safety testing, more transparency about side-effects, and improved patient communication to allay patient concerns about safety. Let’s hope that history does not repeat itself because Lyme vaccine manufacturers, regulators, and promoters once again underestimate or ignore justified patient concerns about Lyme vaccination risks.”10

Please read Dr. Stricker’s comment about the vaccine:  Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis.

And here, it states that Valneva VLA15 is a multivalent recombinant OspA based vaccine against Lyme Borreliosis:

Valneva does not use the epitope that was associated with autoimmune reactions that were alleged to occur with LYMErix, Shaffer explains.

Meanwhile, Marconi’s vaccine is targeting an entirely different OspC and is “anticipating better acceptance of such a vaccine because of its track record in pets.” An OspC vaccine has been challenging, in part, due to highly variable protein between strains.

Note: Neither of the new vaccines described by Shaffer addresses protection against co-infections.

Valneva states this regarding its press release:

In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements.